1 Ha, H, Oh, EY & Lee, HB (2009) The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 5, 203–211.
2 Senno, SL & Pechet, L (1999) Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature. J Thromb Thrombolysis 8, 105–112.
3 Folsom, AR, Aleksic, N, Park, E, et al. (2001) Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1, 611–617.
4 Thogersen, AM, Jansson, JH, Boman, K, et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241–2247.
5 Oh, K, Hu, FB, Manson, JE, et al. (2005) Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses' health study. Am J Epidemiol 161, 672–679.
6 Harris, WS, Poston, WC & Haddock, CK (2007) Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193, 1–10.
7 Laaksonen, DE, Nyyssonen, K, Niskanen, L, et al. (2005) Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med 165, 193–199.
8 Zhao, WS, Zhai, JJ, Wang, YH, et al. (2009) Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension. Am J Hypertens 22, 680–686.
9 Knapp, HR (1997) Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 65, Suppl. 5, 1687–1698S.
10 Laaksonen, DE, Lakka, TA, Lakka, HM, et al. (2002) Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 19, 456–464.
11 Calder, PC (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791–795.
12 Nelson, GJ, Kelley, DS, Emken, EA, et al. (1997) A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design. Lipids 32, 415–420.
13 Harris, WS, Mozaffarian, D, Rimm, E, et al. (2009) Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119, 902–907.
14 Willett, WC (2007) The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J Cardiovasc Med (Hagerstown) 8, Suppl. 1, S42–S45.
15 Kohler, HP & Grant, PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342, 1792–1801.
16 Levenson, J, Giral, P, Razavian, M, et al. (1995) Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 15, 1263–1268.
17 Sekikawa, A, Ueshima, H, Kadowaki, T, et al. (2007) Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol 165, 617–624.
18 Kagan, A (1996) . New York: Harwood Academic Press.
19 Abbott, RD, Ueshima, H, Rodriguez, BL, et al. (2007) Coronary artery calcification in Japanese men in Japan and Hawaii. Am J Epidemiol 166, 1280–1287.
20 Declerck, PJ & Collen, D (1990) Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl 10, 3–9.
21 Macy, EM, Meilahn, EN, Declerck, PJ, et al. (1993) Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 117, 67–70.
22 Declerck, PJ, Alessi, MC, Verstreken, M, et al. (1988) Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71, 220–225.
23 Sekikawa, A, Curb, JD, Ueshima, H, et al. (2008) Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 52, 417–424.
24 Fleischman, AI, Justice, D, Bierenbaum, ML, et al. (1975) Beneficial effect of increased dietary linoleate upon in vivo platelet function in man. J Nutr 105, 1286–1290.
25 O'Brien, JR, Etherington, MD & Jamieson, S (1976) Effect of a diet of polyunsaturated fats on some platelet-function tests. Lancet 2, 995–996.
26 Byberg, L, Smedman, A, Vessby, B, et al. (2001) Plasminogen activator inhibitor-1 and relations to fatty acid composition in the diet and in serum cholesterol esters. Arterioscler Thromb Vasc Biol 21, 2086–2092.
27 Thijssen, MA, Hornstra, G & Mensink, RP (2005) Stearic, oleic, and linoleic acids have comparable effects on markers of thrombotic tendency in healthy human subjects. J Nutr 135, 2805–2811.
28 Banfi, C, Rise, P, Mussoni, L, et al. (1997) Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. J Lipid Res 38, 860–869.
29 Ye, P, He, YL, Wang, Q, et al. (2007) The alteration of plasminogen activator inhibitor-1 expression by linoleic acid and fenofibrate in HepG2 cells. Blood Coagul Fibrinolysis 18, 15–19.
30 Bates, EJ, Ferrante, A, Smithers, L, et al. (1995) Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells. Atherosclerosis 116, 247–259.
31 Sinha, B, Stoll, D, Weber, PC, et al. (1991) Polyunsaturated fatty acids modulate synthesis of TNF-[alpha] and interleukin-1[beta] by human MNC in vitro. Cytokine 3, 457–457.
32 Kusumoto, A, Ishikura, Y, Kawashima, H, et al. (2007) Effects of arachidonate-enriched triacylglycerol supplementation on serum fatty acids and platelet aggregation in healthy male subjects with a fish diet. Br J Nutr 8, 626–635.
33 Nelson, GJ, Schmidt, PC, Bartolini, G, et al. (1997) The effect of dietary arachidonic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 2, 421–425.
34 Schmitz, G & Ecker, J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 7, 147–155.
35 Choo, J, Ueshima, H, Curb, JD, et al. (2010) Serum n-6 fatty acids and lipoprotein subclasses in middle-aged men: the population-based cross-sectional ERA-JUMP study. Am J Clin Nutr 1, 1195–1203.
36 Nilsson, L, Gafvels, M, Musakka, L, et al. (1999) VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res 40, 913–919.
37 Willett, WC, Howe, GR & Kushi, LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65, 1220S–11228.